- Home
- STKS vs ANVS Comparison
STKS vs ANVS Comparison
Compare STKS & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STKS | ANVS |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.4M | 69.1M |
| IPO Year | 2011 | 2019 |
Fundamental Metrics
Financial Performance| Metric | STKS | ANVS |
|---|---|---|
| Price | $2.00 | $1.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $4.70 | ★ $13.50 |
| AVG Volume (30 Days) | 20.2K | ★ 991.0K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $805,722,000.00 | N/A |
| Revenue This Year | $7.47 | N/A |
| Revenue Next Year | $8.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.66 | N/A |
| 52 Week Low | $1.65 | $1.54 |
| 52 Week High | $4.12 | $5.50 |
Technical Indicators
Market Signals| Indicator | STKS | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 55.36 | 46.27 |
| Support Level | $1.71 | $1.66 |
| Resistance Level | $2.06 | $2.12 |
| Average True Range (ATR) | 0.13 | 0.13 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 56.96 | 27.62 |
Price Performance
Historical ComparisonAbout STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through three segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.